Overview

* Clover Health Q2 2025 rev grows 34% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 beats consensus, reaching $17 mln

* Company reports GAAP net loss of $11 mln for Q2

Outlook

* Clover Health maintains full-year insurance revenue guidance at $1.800 bln - $1.875 bln

* Company improves full-year Adjusted SG&A to $335 mln - $345 mln

* Clover Health expects Insurance BER between 88.5% - 89.5%

* Company anticipates average Medicare Advantage membership of 104,000 - 108,000

Result Drivers

* TECHNOLOGY-FIRST MODEL - Co attributes growth to technology-first model, focusing on affordability and AI-driven clinical recommendations, per CEO Andrew Toy

* MEMBERSHIP GROWTH - Medicare Advantage membership increased by 32% yr/yr, reaching 106,323 members

* CLOVER ASSISTANT IMPACT - Co reports improved health outcomes with Clover Assistant technology, citing fewer hospitalizations and readmissions for COPD

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $478 mln $468.30

Revenue mln (4

Analysts

)

Q2 Net -$11 mln

Income

Q2 Beat $17 mln $16.30

Adjusted mln (4

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the managed healthcare peer group is "buy."

* Wall Street's median 12-month price target for Clover Health Investments Corp ( CLOV ) is $4.50, about 36% above its August 4 closing price of $2.88

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)